Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TQB 3909

Next Previous
Drug Profile

TQB 3909

Alternative Names: TQB-3909

Latest Information Update: 16 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chia Tai Tianqing Pharmaceutical Group
  • Class Antineoplastics
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Lymphoid leukaemia; Mantle-cell lymphoma; Myelodysplastic syndromes; Myelofibrosis; Solid tumours

Most Recent Events

  • 30 Dec 2025 Chia Tai Tianqing Pharmaceutical terminates a phase I/II trial in Myelofibrosis (Combination therapy, Monotherapy) in China (PO) as per sponsor request(NCT06245941)
  • 06 Dec 2025 Adverse events and efficacy data from a phase I/II trial in Myelofibrosis presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
  • 06 Dec 2025 Efficacy and adverse events data from a phase I/II trial in Acute myeloid leukaemia presented at the 67th American Society of Hematology Annual Meeting and Exposition Session (ASH-Hem-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top